Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evaxion Biotech ( (EVAX) ) has issued an announcement.
On April 7, 2026, Evaxion announced it has completed the one-year extension of its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma, with the last patient having had their final physician visit. The study design allows evaluation of EVX-01 both in combination with Keytruda and as a monotherapy, potentially strengthening Evaxion’s position in AI-designed cancer vaccines as it prepares three-year data for release in the second half of 2026.
The trial has already produced encouraging one- and two-year results, including a 75% Objective Response Rate, with 12 of 16 patients responding and four achieving complete responses. Durable benefit was observed, with 92% of patients still responding at two years, no relapses reported, high tumor reduction rates, and strong neoantigen-specific T-cell responses, underscoring both the tolerability of EVX-01 and the precision of Evaxion’s AI-Immunology platform.
The most recent analyst rating on (EVAX) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Denmark-based clinical-stage TechBio company that uses its proprietary, clinically validated AI-Immunology platform to design novel vaccines for cancer and infectious diseases. The company’s pipeline includes both personalized and off-the-shelf cancer vaccines, as well as prophylactic candidates, targeting high unmet medical needs in oncology and infectious disease markets.
Average Trading Volume: 45,427
Technical Sentiment Signal: Sell
Current Market Cap: $31.07M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.